Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network
| dc.rights.license | open | en_US |
| dc.contributor.author | JABBOUR, Matthieu | |
| dc.contributor.author | KODJIKIAN, Laurent | |
| dc.contributor.author | BOURDIN, Alexandre | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ROUGIER, Marie-Benedicte | |
| dc.contributor.author | SERRAR, Yasmine | |
| dc.contributor.author | WEBER, Michel | |
| dc.contributor.author | MASSE, Helene | |
| dc.contributor.author | MAZHAR, Driss | |
| dc.contributor.author | PEREZ-ROUSTIT, Sara | |
| dc.contributor.author | CHIQUET, Christophe | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DELYFER, Marie-Noelle | |
| dc.contributor.author | BODAGHI, Bahram | |
| dc.contributor.author | TOUHAMI, Sara | |
| dc.date.accessioned | 2024-05-06T09:21:53Z | |
| dc.date.available | 2024-05-06T09:21:53Z | |
| dc.date.issued | 2024-02-24 | |
| dc.identifier.issn | 2075-4426 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/199641 | |
| dc.description.abstractEn | PURPOSE: To evaluate the safety and efficacy of the fluocinolone acetonide implant (FAi, Iluvien(®) Horus pharma, Nice, France) in non-infectious uveitic macular edema (UME) and to approach the predictive factors of treatment response. METHODS: This retrospective, multicenter real-life study included patients with chronic non-infectious UME who received intravitreal FAi after at least two dexamethasone implants (DEXi). RESULTS: Twenty-six eyes from 22 patients (73.1% of females) were included. The mean age was 60.4 ± 16 years. The mean follow-up was 11.4 ± 2 months. The mean baseline best-corrected visual acuity (BCVA) was 0.43 ± 0.36 LogMAR, improving significantly after 1, 3, 6 and 12 months (all p < 0.05 vs. baseline). The mean baseline central macular thickness (CMT) was 429 ± 110 μm, improving significantly after 1, 3, 6 and 12 months (all p < 0.05 vs. baseline). Five eyes (19.2%) developed ocular hypertension during the follow-up, requiring initiation or strengthening of intraocular pressure lowering medication. The majority of eyes (77%) did not require any rescue DEXi during the available 12-month follow-up. The resolution of UME after DEXi seemed to predict the anatomical response after FAi. The baseline presence of a disorganization of the inner retinal layers (DRIL) and hyperreflective foci (HRF) were both associated with a higher likelihood of requiring rescue DEXi injections. CONCLUSION: FAi implantation led to a significant BCVA and CMT improvement with a good safety profile over the 12-month follow-up. Predictive factors of treatment outcomes seem to include the anatomical response to DEXi and the presence of DRIL and HRF at baseline. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | DRIL | |
| dc.subject.en | Chronic non-infectious uveitis | |
| dc.subject.en | Dexamethasone | |
| dc.subject.en | Fluocinolone acetonide implant | |
| dc.subject.en | Hyperreflective foci | |
| dc.subject.en | Predictive factor | |
| dc.subject.en | Uveitic macular edema | |
| dc.title.en | Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network | |
| dc.title.alternative | J Pers Med | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/jpm14030245 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38540987 | en_US |
| bordeaux.journal | Journal of Personalized Medicine | en_US |
| bordeaux.volume | 14 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 3 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04569166 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-05-06T09:21:56Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Personalized%20Medicine&rft.date=2024-02-24&rft.volume=14&rft.issue=3&rft.eissn=2075-4426&rft.issn=2075-4426&rft.au=JABBOUR,%20Matthieu&KODJIKIAN,%20Laurent&BOURDIN,%20Alexandre&ROUGIER,%20Marie-Benedicte&SERRAR,%20Yasmine&rft.genre=article |
